BMY BMS revenue slips slightly in Q1 2026 as drug sales soften stock dips marginally ITOC iTonic reports quarterly results as CEO emphasizes transformation strategy and AI integration roadmap ADIL Adial Pharmaceuticals Inc reports wider than expected Q4 2025 loss yet stock notches 253 percent gain today